A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)
NCT03615482
Completed
This study was designed to evaluate the safety and tolerability of a single dose of V114 when administered concomitantly and non-concomitantly (i.e., 30 days after) with influenza vaccine. It also evaluated whether V114 can be administered concomitantly with influenza vaccine without impairing the antibody response to the 15 serotypes contained in V114 and to the 4 influenza viruses contained in the seasonal inactivated quadrivalent influenza vaccine (QIV). The primary hypotheses state that immu... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/20/2024
Locations: Achieve Clinical Research, LLC ( Site 0046), Birmingham, Alabama +44 locations
Conditions: Pneumococcal Infections
Register for Updates
Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
NCT04491877
Completed
The primary objectives of the study were: * To assess the safety profile of each dose of the study product after each and any administration in all infants and toddlers regardless of baseline serostatus. * To characterize the Respiratory Syncytial Virus (RSV) A serum neutralizing antibody responses to the study product in each vaccine group after vaccination in RSV-naïve participants. The secondary objectives of the study were: * To quantify the amount of vaccine virus shed by each participan... Read More
Gender:
ALL
Ages:
Between 6 months and 18 months
Trial Updated:
05/20/2024
Locations: Matrix Clinical Research-Site Number:8400012, Gardena, California +28 locations
Conditions: Respiratory Syncytial Virus Infection
Register for Updates
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
NCT05101356
Recruiting
This phase 1/2 trial tests the safety and effectiveness of a cancer vaccine called Labvax 3(22)-23 and GM-CSF alone or in combination with pembrolizumab in treating adenocarcinoma that has spread to other places in the body (advanced stage). Labvax 3(22)-23 is designed to target a specific antigen (labyrinthin), which is a protein found on the surface of adenocarcinoma tumor cells. Labyrinthin is a protein that is not expressed on normal cells in the skin, lungs, salivary glands, pancreas, nor o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2024
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Advanced Adenocarcinoma, Advanced Malignant Solid Neoplasm, Metastatic Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Adenocarcinoma, Recurrent Malignant Solid Neoplasm
Register for Updates
The Impact of COVID-19 on Maternal and Neonatal Outcomes
NCT05197621
Recruiting
The novel coronavirus (SARS-CoV-2) infection (COVID-19) has caused a worldwide pandemic. There is still much that is unknown regarding the virus, especially its effects on pregnancy, the fetus, and the neonate. This study seeks to evaluate adverse pregnancy and neonatal outcomes related to COVID-19 infection. The FDA has authorized emergency use authorization for the SARS-CoV-2 messenger ribonucleic acid (mRNA) vaccines from Pfizer and Moderna. Pregnant women were excluded from the Phase III cl... Read More
Gender:
FEMALE
Ages:
Between 14 years and 55 years
Trial Updated:
05/16/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: COVID-19, Pregnancy; Infection
Register for Updates
PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
NCT03299309
Active Not Recruiting
The primary goal of this prospective clinical trial is to evaluate the safety of PEP-CMV in patients with recurrent medulloblastoma and malignant glioma. Patients with histologically-proven medulloblastoma or malignant glioma who had received prior therapy for their initial diagnosis and subsequently had tumor recurrence/progression may be enrolled any time after recurrence/progression regardless of prior adjuvant therapy. PEP-CMV is a vaccine comprised of Component A, a synthetic long peptide (... Read More
Gender:
ALL
Ages:
Between 3 years and 35 years
Trial Updated:
05/09/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Recurrent Medulloblastoma, Recurrent Brain Tumor, Childhood, Malignant Glioma
Register for Updates
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
NCT02728102
Completed
The study is designed as a Phase II, multicenter trial of vaccination with Dendritic cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide maintenance therapy versus maintenance therapy alone or with GM-CSF following autologous transplant as part of upfront treatment of multiple myeloma (MM). It is hypothesized that the dendritic cell myeloma vaccine will result in improved response in patients with multiple myeloma after autologous Hemato... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/03/2024
Locations: University of California, San Francisco, San Francisco, California +14 locations
Conditions: Multiple Myeloma
Register for Updates
Postpartum Integration of Vaccines and Contraception Trial
NCT05732142
Recruiting
This study aims to examine how to implement a gender-transformative post-partum family planning program integrated into community-based infant vaccination services, and to evaluate preliminary effectiveness of this approach on postpartum contraceptive use in a low resource, rural setting.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: University of California, San Diego, La Jolla, California +1 locations
Conditions: Contraception, Gender Equity
Register for Updates
Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older
NCT05639894
Active Not Recruiting
Brief Summary of Stage 1: The purpose Stage 1 (Phase I/IIa) is to assess the safety and immunogenicity of a single intramuscular (IM) injection of 3 dose-levels of an Respiratory Syncytial Virus (RSV) vaccine candidate formulated with 2 different lipid nanoparticles (LNPs) in healthy adult participants aged between 18 to 50 years, and 60 years and older. The primary objectives of this stage are to assess the safety and immunogenicity profiles across the dose-level groups (low, medium, and high... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Accel Research Site - Birmingham Clinical Research Unit Site Number : 8400037, Birmingham, Alabama +36 locations
Conditions: Respiratory Syncytial Virus Immunization
Register for Updates
A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)
NCT05001373
Active Not Recruiting
A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good General Health
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/29/2024
Locations: George Washington University, Washington, District of Columbia +3 locations
Conditions: Hiv
Register for Updates
Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women
NCT04766086
Completed
This phase 2B, placebo-controlled, randomized, observer-blinded trial will evaluate the safety, tolerability, and immunogenicity of the investigational multivalent group B streptococcus vaccine administered concomitantly with Tdap in healthy nonpregnant women 18 through 49 years of age.
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
04/25/2024
Locations: Alliance for Multispecialty Research, LLC, Newton, Kansas +11 locations
Conditions: Group B Streptococcus Infections
Register for Updates
An Open Label Study of IgG Fc Glycan Composition in Human Immunity
NCT01967238
Terminated
In order to produce better more effective vaccines, it is important to understand the particulars of why individuals have an effective or ineffective immune response to vaccination. We are going to examine specific aspects of the antibody (IgG Fc glycan) made by healthy volunteers who receive different vaccines or who have a viral infection to understand the nature of an effective (or less effective) vaccine response. The results of this research could be used to develop adjuvants to increase/ i... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/23/2024
Locations: The Rockefeller University, New York, New York
Conditions: Healthy
Register for Updates
Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.
NCT05630859
Active Not Recruiting
The aim of this first time in human proof of concept (FTiH-PoC) study is to evaluate safety and reactogenicity, to demonstrate efficacy and to explore immunogenicity of GlaxoSmithKline's (GSK) Neisseria gonorrhoeae generalized modules for membrane antigens (GMMA) (NgG) investigational vaccine compared to placebo (saline).
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/19/2024
Locations: GSK Investigational Site, Washington, District of Columbia +22 locations
Conditions: Sexually Transmitted Diseases
Register for Updates